Nenocorilant

$580$3,000

Products Details

Product Description

– Nenocorilant (Relacorilant) is a potent, orally activity glucocorticoid receptor (GR) antagonist with Ki value of 0.15 nM. Nenocorilant has pro-apoptotic effects and improves potency combined with cytotoxic agent. Nenocorilant can be used for cancer research[1][2][3].

Web ID

– HY-147293

Storage Temperature

– -20°C, 3 years; 4°C, 2 years (Powder)

Shipping

– Room Temperature

Applications

– Cancer-programmed cell death

Molecular Formula

– C26H21F4N7O3S

References

– [1]Greenstein AE, et, al. Glucocorticoid receptor antagonism promotes apoptosis in solid tumor cells. Oncotarget. 2021 Jun 22;12(13):1243-1255.|[2]Stringer-Reasor EM, et, al. Glucocorticoid receptor activation inhibits chemotherapy-induced cell death in high-grade serous ovarian carcinoma. Gynecol Oncol. 2015 Sep;138(3):656-62.|[3]WHO Drug Information. International Nonproprietary Names for Pharmaceutical

CAS Number

– 1496509-78-4

Molecular Weight

– 587.55

Compound Purity

– 99.72

SMILES

– O=C(C1=CC(C(F)(F)F)=CC=N1)[C@@]23C(CCN(C3)S(=O)(C4=NN(N=C4)C)=O)=CC5=C(C=NN5C6=CC=C(C=C6)F)C2

Clinical Information

– Phase 3

Research Area

– Cancer

Solubility

– 10 mM in DMSO

Target

– Apoptosis;Caspase;Glucocorticoid Receptor

Pathway

– Apoptosis;Immunology/Inflammation;Vitamin D Related/Nuclear Receptor

Product type

– Reference compound

Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.

My Cart
Close Wishlist
Close Recently Viewed
Categories

Please fill out this form to request the file. We will send it to your Email address shortly. Thanks.

Please enable JavaScript in your browser to complete this form.

=

Please fill out this form to request the pricing.
We will send it to your email address shortly.
Thanks.

Please enable JavaScript in your browser to complete this form.

=